CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of CT-011. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of CT-011. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of CT-011. |
| Estrone | Estrone may increase the thrombogenic activities of CT-011. |
| Estradiol | Estradiol may increase the thrombogenic activities of CT-011. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of CT-011. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of CT-011. |
| Mestranol | Mestranol may increase the thrombogenic activities of CT-011. |
| Estriol | Estriol may increase the thrombogenic activities of CT-011. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of CT-011. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of CT-011. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of CT-011. |
| Tibolone | Tibolone may increase the thrombogenic activities of CT-011. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of CT-011. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of CT-011. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of CT-011. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of CT-011. |
| Zeranol | Zeranol may increase the thrombogenic activities of CT-011. |
| Equol | Equol may increase the thrombogenic activities of CT-011. |
| Promestriene | Promestriene may increase the thrombogenic activities of CT-011. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of CT-011. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of CT-011. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of CT-011. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of CT-011. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of CT-011. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of CT-011. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of CT-011. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of CT-011. |
| Formononetin | Formononetin may increase the thrombogenic activities of CT-011. |
| Estetrol | Estetrol may increase the thrombogenic activities of CT-011. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with CT-011. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CT-011. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with CT-011. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with CT-011. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with CT-011. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CT-011. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CT-011. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with CT-011. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with CT-011. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with CT-011. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with CT-011. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with CT-011. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CT-011. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CT-011. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with CT-011. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CT-011. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CT-011. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with CT-011. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CT-011. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with CT-011. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with CT-011. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with CT-011. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with CT-011. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CT-011. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with CT-011. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with CT-011. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with CT-011. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with CT-011. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with CT-011. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with CT-011. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with CT-011. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with CT-011. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with CT-011. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with CT-011. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with CT-011. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with CT-011. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with CT-011. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with CT-011. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with CT-011. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with CT-011. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with CT-011. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with CT-011. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with CT-011. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with CT-011. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with CT-011. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with CT-011. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with CT-011. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with CT-011. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with CT-011. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with CT-011. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with CT-011. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with CT-011. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with CT-011. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with CT-011. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with CT-011. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with CT-011. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with CT-011. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with CT-011. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with CT-011. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when CT-011 is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when CT-011 is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when CT-011 is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when CT-011 is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when CT-011 is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when CT-011 is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when CT-011 is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when CT-011 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when CT-011 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when CT-011 is combined with Canakinumab. |